Antibodies

Items 231-240 of 256

per page
Set Descending Direction
  1. anti-Streptavidin, made in goat, biotinylated
    VC-BA-0500
    VC-BA-0500-MC050.5 mg
    CHF 263.00
  2. anti-Streptavidin, made in goat, DyLight 488
    VC-SP-4488
    VC-SP-4488-MC050.5 mg
    CHF 263.00
  3. anti-Streptavidin, made in goat, Unconjugated
    VC-SP-4000
    VC-SP-4000-M0011 mg
    CHF 236.00
  4. anti-TDO (human), pAb
    AG-25A-0106
    AG-25A-0106-C100100 µg
    CHF 190.00
    Western blot analysis using anti-TDO (human), pAb (Prod. No. AG-25A-0106) at 1:2'000 dilution.
1: Human TDO (His-tagged).
2: Human IDO (His-tagged).
3: Mouse IDO (His-tagged).
4: SH-sy5y cell lysate.
5: Unrelated protein (His
  5. anti-TRAM (human), pAb (AL239)
    AG-25B-0011
    AG-25B-0011-R05050 µl
    CHF 130.00
  6. anti-TRB-3 (human), pAb
    AG-25A-0059
    AG-25A-0059-C100100 µg
    CHF 190.00
    Western blot analysis of human tissue lysate using anti-TRB3 (human), pAb (Prod. No. AG-25A-0059) at 1:2,000 dilution.
1. Human spleen tissue lysate (10μg).
2. Human liver tissue lysate (10μg)
3. Human colon tissue lysate (10μg)
  7. anti-Tubulin (glycylated), pAb (Gly-pep1)
    AG-25B-0034
    AG-25B-0034-C100100 µg
    CHF 440.00
    Immunoblot analysis of protein glycylation using anti-Tubulin (glycylated), pAb (Gly-pep1) (Prod. No. AG-25B-0034). Method: HEK-293T cells are grown in standard culture conditions, transfected with plasmids expressing the glycylases TTLL3 and TTLL8
  8. anti-VASP (human), pAb
    AG-25T-0112
    AG-25T-0112-R100100 µl
    CHF 280.00
  9. anti-VASP, pAb (IG-731)
    AG-25T-0109
    AG-25T-0109-C02525 µg
    CHF 520.00
  10. anti-Vaspin (human), pAb
    AG-25A-0048
    AG-25A-0048-C100100 µg
    CHF 450.00
    Western blot analysis using anti-Vaspin (human), pAb (Prod. No. AG-25A-0048) at 1:2'000 dilution.
1: Human Vaspin (His-tagged).
2: Human Vaspin (FLAG®-tagged).
3: Mouse IL-33 (His-tagged) (negative control).

Items 231-240 of 256

per page
Set Descending Direction
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.